A Phase 3 interventional study of Avelox (Moxifloxacin, BAY12-8039) and Ceftriaxone; Azithromycin; Amoxicilline/clavulanate; Clarithromycin in Pneumonia, sponsored by Bayer. Completed at 23 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-11-04.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Community-Acquired Pneumonia with a site in Italy — 6 open to participants now, 6 under way, 2 of them phase 3. Community-Acquired Pneumonia · Italy.
Among the 17 studies in Community-Acquired Pneumonia with a site in Italy, this one is the only one that started in 2008, is one of 4 in phase 3, and was the 2nd registered.
325 studies on the registry are indexed under Community-Acquired Pneumonia; 78 are open to participants now.
Browse Community-Acquired Pneumonia studies →6 of the 17 studies in Community-Acquired Pneumonia with a site in Italy are open now. Recruiting first, the newest first:
Azienda Ospedaliero-Universitaria Careggi · Sites in Italy
Ages 18–90
Societa Italiana di Pneumologia · Sites in Italy
Ages 18+
University of Oxford · Sites in Italy, Belgium, Estonia and 13 more countries
Ages 0+
University of Trieste · Sites in Italy
Ages 18+
UMC Utrecht · Sites in Italy, United States, Australia and 26 more countries
Ages 28 days+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 41 Community-Acquired Pneumonia studies recruiting now, 29 (71%) set no upper age limit and 9 (22%) stop at 75 or younger; 13 take children under 18; 5 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 60 is below the median of 246 across 196 interventional studies indexed under Community-Acquired Pneumonia.
Median enrollment 507 across the 6 interventional studies, 500 across the 11 observational. Of the 8 that completed or were terminated, 2 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 17 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Bayer has 5 studies filed under Community-Acquired Pneumonia — fewer than ten, so there is no comparison to draw.
1 of the studies in Community-Acquired Pneumonia with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07070284Joan Sabater-RieraESCAPE10: Epidemiology, Risk Factors, and Outcomes of Severe Community-acquired Pneumonia in Elderly Patients Acquired Pneumonia in Elderly Patients | 2026-11-30 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies in Community-Acquired Pneumonia with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess if a therapy with oral and intravenous moxifloxacin is as effective as a therapy with intravenous ceftriaxone + intravenous azithromycin followed by oral amoxicilline/clavulanate and oral clarithromycin in the treatment of community-acquired pneumonia.
325 studies on the registry are indexed under Community-Acquired Pneumonia; 78 are open to participants now.
This study's enrollment of 60 is below the median of 246 across 196 interventional studies indexed under Community-Acquired Pneumonia.
Browse Community-Acquired Pneumonia studies →Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.
Compared within Community-Acquired Pneumonia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pneumonia. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
At least 2 of the following conditions:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Avelox (Moxifloxacin, BAY12-8039)
Drug: Ceftriaxone; Azithromycin; Amoxicilline/clavulanate; Clarithromycin
IV therapy: every 24 hours, patients will be administered a 400 mg moxifloxacin infusion over 60 minutes. Oral therapy: patients will be administered a single moxifloxacin 400 mg tablet, every 24 hours
Drug pages: Ceftriaxone · Azithromycin · Amoxicillin · Clavulanic Acid · Clarithromycin
IV therapy: every 24 hours patients will be administered a 2 g ceftriaxone infusion over 30 minutes. Following the infusion with ceftriaxone, patients will be administered a 500 mg azithromycin infusion over 180 minutes.Oral therapy: every 8 hours patients will be administered a 1000 mg amoxicillin/clavulanic acid tablet. Every 12 hours patients will be administered a 500 mg clarithromycin tablet.
Clinical response 20 days after completion of study treatment (Test-of-Cure visit)
Time frame: 20 days after last dose of study drug (TOC Visit)
Clinical and bacteriological response on the day of switch from IV to oral therapy
Time frame: Day of switch from IV to oral therapy
Clinical and bacteriological response on treatment Day 3-5 (if the day of switch is different from Day 3, 4 or 5)
Time frame: Day 3-5
Bacteriological response at TOC
Time frame: 20 days after last dose of study drug
Clinical and bacteriological response at the end of treatment
Time frame: Day 7-14 after first dose of study drug
Mortality attributable to pneumonia at the Test-of-Cure visit
Time frame: 20 days after last dose of study drug
The record gives a start of Feb 2008, a primary completion of May 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Moxifloxacin
Community-Acquired Pneumonia →